NASDAQ:RVMD

Revolution Medicines (RVMD) Stock Forecast, Price & News

$25.30

-1.61 (-5.98%)

(As of 02:40 PM ET)

Compare

Today's Range: $24.76
▼
$26.98
50-Day Range: $20.28
▼
$27.00
52-Week Range: $15.64
▼
$31.37

Volume: 386,530 shs
Average Volume: 1.11 million shs
Market Capitalization: $2.69 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $33.00

Revolution Medicines MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 31.0% Upside
$33.00 Price Target
Short Interest: Bearish
8.88% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: 0.65
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$2.05 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.47) to ($3.71) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

701st out of 981 stocks

Biological Products, Except Diagnostic Industry

115th out of 164 stocks

3.4

Analyst's Opinion

Consensus Rating
Revolution Medicines has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $33.00, Revolution Medicines has a forecasted upside of 31.0% from its current price of $25.19.
Amount of Analyst Coverage
Revolution Medicines has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.88% of the outstanding shares of Revolution Medicines have been sold short.
Short Interest Ratio / Days to Cover
Revolution Medicines has a short interest ratio ("days to cover") of 7.7.
Change versus previous month
Short interest in Revolution Medicines has recently decreased by 1.87%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Revolution Medicines does not currently pay a dividend.
Dividend Growth
Revolution Medicines does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Revolution Medicines has received a 74.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Revolution Medicines is -0.81.

2.6

News and Social Media Coverage

News Sentiment
Revolution Medicines has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Revolution Medicines this week, compared to 2 articles on an average week.
MarketBeat Follows
1 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Revolution Medicines insiders have bought 4,857.24% more of their company's stock than they have sold. Specifically, they have bought $2,046,000.00 in company stock and sold $41,273.00 in company stock.
Percentage Held by Insiders
Only 8.50% of the stock of Revolution Medicines is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Revolution Medicines are expected to decrease in the coming year, from ($3.47) to ($3.71) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Revolution Medicines is -8.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Revolution Medicines is -8.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Revolution Medicines has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

RVMD Stock News Headlines

May 24, 2023 | finance.yahoo.com

Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit

May 18, 2023 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Shares Down 5%

June 8, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

May 18, 2023 | americanbankingnews.com

Analysts Set Revolution Medicines, Inc. (NASDAQ:RVMD) PT at $31.88

May 13, 2023 | finance.yahoo.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Trimmed Their Revenue Forecasts By 25%

May 13, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Revolution Medicines, Inc. (NASDAQ:RVMD) Decreased by Analyst

May 11, 2023 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) PT Lowered to $35.00

May 10, 2023 | finance.yahoo.com

Revolution Medicines First Quarter 2023 Earnings: Beats Expectations

June 8, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

May 9, 2023 | finanznachrichten.de

Revolution Medicines, Inc.: Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

May 9, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Revolution Medicines

May 9, 2023 | finance.yahoo.com

Q1 2023 Revolution Medicines Inc Earnings Call

May 8, 2023 | seekingalpha.com

Revolution Medicines, Inc. (RVMD) Q1 2023 Earnings Call Transcript

May 8, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xencor (XNCR) and Revolution Medicines (RVMD)

May 3, 2023 | finance.yahoo.com

Wall Street Analysts Think Revolution Medicines, Inc. (RVMD) Could Surge 27.24%: Read This Before Placing a Bet

May 1, 2023 | finance.yahoo.com

Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023

May 1, 2023 | finance.yahoo.com

Revolution Medicines, Inc. (RVMD) Expected to Beat Earnings Estimates: Should You Buy?

April 25, 2023 | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $32.25 Average Price Target from Analysts

April 19, 2023 | finance.yahoo.com

Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns climbed after last week's 16% gain, institutional investors must be happy

April 17, 2023 | seekingalpha.com

Revolution Medicines: Advancing On Several Fronts

April 16, 2023 | americanbankingnews.com

HC Wainwright Reiterates Buy Rating for Revolution Medicines (NASDAQ:RVMD)

April 15, 2023 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Trading 7.6% Higher

April 14, 2023 | americanbankingnews.com

HC Wainwright Weighs in on Revolution Medicines, Inc.'s Q1 2023 Earnings (NASDAQ:RVMD)

April 13, 2023 | finance.yahoo.com

Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

April 12, 2023 | msn.com

HC Wainwright & Co. Reiterates Revolution Medicines (RVMD) Buy Recommendation

April 12, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Revolution Medicines (RVMD)

April 6, 2023 | finance.yahoo.com

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

See More Headlines

RVMD Price History

30 days | 90 days | 365 days | Advanced Chart

RVMD Company Calendar

Last Earnings: 5/08/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RVMD
CUSIP: N/A
CIK: 1628171
Web: www.revmed.com
Phone: 650-481-6801
Fax: N/A
Employees: 188
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $33.00
High Stock Price Forecast: $38.00
Low Stock Price Forecast: $23.00
Forecasted Upside/Downside: +29.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-248,710,000.00
Net Margins: -744.36%
Pretax Margin: -745.57%
Return on Equity: -36.79%
Return on Assets: -31.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.89
Quick Ratio: 16.89

Sales & Book Value

Annual Sales: $35.38 million
Price / Sales: 76.38
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.72 per share
Price / Book: 3.29

Miscellaneous

Outstanding Shares: 106,310,000
Free Float: 97,276,000
Market Cap: $2.70 billion
Optionable: Not Optionable
Beta: 1.44

Key Executives

Dr. Mark A. Goldsmith Ph.D. (Age 61)
CEO, Pres & Chairman
Comp: $1.01M

Mr. Jack Anders (Age 46)
Chief Financial Officer
Comp: $462.13k

Ms. Margaret A. Horn J.D. (Age 60)
Chief Operating Officer
Comp: $773.03k

Dr. Stephen M. Kelsey FRC Path. (Age 62)
FRCP, M.D., Pres of R&D
Comp: $773.03k

Ms. Xiaolin Wang (Age 52)
Exec. VP of Clinical Devel.
Comp: $582.43k

Dr. Martin D. Burke M.D.
Ph.D., Co-Founder & Chairman of Scientific Advisory Board

Dr. Michael A. Fischbach Ph.D. (Age 42)
Academic Co-Founder & Member of Scientific Advisory Board

Dr. Kevan M. Shokat Ph.D.
Academic Co-Founder & Member of Scientific Advisory Board

Mr. David L. Pompliano Ph.D.
Founding Chief Scientific Officer

Mr. Walter Reiher Ph.D.
Chief Information Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RVMD Stock - Frequently Asked Questions

Should I buy or sell Revolution Medicines stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVMD shares.
View RVMD analyst ratings or view top-rated stocks.
What is Revolution Medicines' stock price forecast for 2023?: 7 brokerages have issued 1 year price objectives for Revolution Medicines' shares. Their RVMD share price forecasts range from $23.00 to $38.00. On average, they anticipate the company's share price to reach $33.00 in the next twelve months. This suggests a possible upside of 29.8% from the stock's current price.
View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts.
How have RVMD shares performed in 2023?: Revolution Medicines' stock was trading at $23.82 on January 1st, 2023. Since then, RVMD shares have increased by 6.7% and is now trading at $25.42.
View the best growth stocks for 2023 here.
When is Revolution Medicines' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our RVMD earnings forecast.
How were Revolution Medicines' earnings last quarter?: Revolution Medicines, Inc. (NASDAQ:RVMD) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.12. The firm earned $7.01 million during the quarter, compared to the consensus estimate of $2.94 million. Revolution Medicines had a negative trailing twelve-month return on equity of 36.79% and a negative net margin of 744.36%. The company's revenue for the quarter was down 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.78) earnings per share.
What ETFs hold Revolution Medicines' stock?: ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED), JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).
What other stocks do shareholders of Revolution Medicines own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

When did Revolution Medicines IPO?: (RVMD) raised $150 million in an IPO on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.
What is Revolution Medicines' stock symbol?: Revolution Medicines trades on the NASDAQ under the ticker symbol "RVMD."
Who are Revolution Medicines' major shareholders?: Revolution Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (9.81%), BlackRock Inc. (7.02%), EcoR1 Capital LLC (5.03%), Price T Rowe Associates Inc. MD (4.74%), BVF Inc. IL (4.66%) and Nextech Invest Ltd. (4.55%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Elizabeth M Anderson, Jack Anders, Jeanna Steele, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder, Vincent A Miller and Xiaolin Wang.
View institutional ownership trends.
How do I buy shares of Revolution Medicines?: Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Revolution Medicines' stock price today?: One share of RVMD stock can currently be purchased for approximately $25.42.
How much money does Revolution Medicines make?: Revolution Medicines (NASDAQ:RVMD) has a market capitalization of $2.70 billion and generates $35.38 million in revenue each year. The company earns $-248,710,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.
How many employees does Revolution Medicines have?: The company employs 188 workers across the globe.
How can I contact Revolution Medicines?: Revolution Medicines' mailing address is 700 Saginaw Drive, Redwood City CA, 94063. The official website for the company is www.revmed.com. The company can be reached via phone at 650-481-6801 or via email at ir@revmed.com.

This page (NASDAQ:RVMD) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial